Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Romiplostim

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Semaxinib, Su5416, 204005-46-9, Su 5416, 194413-58-6, Su-5416
    Molecular Formula
    C15H14N2O
    Molecular Weight
    238.28  g/mol
    InChI Key
    WUWDLXZGHZSWQZ-WQLSENKSSA-N
    FDA UNII
    71IA9S35AJ
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one
    2.1.2 InChI
    InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8-
    2.1.3 InChI Key
    WUWDLXZGHZSWQZ-WQLSENKSSA-N
    2.1.4 Canonical SMILES
    CC1=CC(=C(N1)C=C2C3=CC=CC=C3NC2=O)C
    2.1.5 Isomeric SMILES
    CC1=CC(=C(N1)/C=C\2/C3=CC=CC=C3NC2=O)C
    2.2 Other Identifiers
    2.2.1 UNII
    71IA9S35AJ
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one

    2. Semaxinib

    3. Su 5416

    4. Su-5416

    5. Su5416

    6. Sugen 5416

    2.3.2 Depositor-Supplied Synonyms

    1. Semaxinib

    2. Su5416

    3. 204005-46-9

    4. Su 5416

    5. 194413-58-6

    6. Su-5416

    7. Semoxind

    8. Semaxanib (su5416)

    9. Tsu 16

    10. Z-semaxanib

    11. Nsc-696819

    12. Vegfr2 Kinase Inhibitor Iii

    13. (z)-3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)indolin-2-one

    14. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-1h-indol-2-one

    15. (z)-su 5416

    16. 71ia9s35aj

    17. Chembl276711

    18. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-1,3-dihydro-2h-indol-2-one

    19. 3-(1-(3,5-dimethyl-1h-pyrrol-2-yl)meth-(z)-ylidene)-2-oxo-2,3-dihydroindole

    20. 3-((z)-(3,5-dimethylpyrrol-2-yl)methylene)-2-indolinone

    21. Su005416

    22. Semaxnib

    23. Sugen 5416

    24. 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-1,3-dihydro-2h-indol-2-one

    25. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-2,3-dihydro-1h-indol-2-one

    26. Semaxanib [inn]

    27. Semaxanib(su5416)

    28. Smr000568416

    29. Vegf Receptor 2 Kinase Inhibitor Iii

    30. Tsu-16

    31. Sr-01000076044

    32. Semaxanib (usan/inn)

    33. Semaxanib [usan:inn]

    34. Methylene]-2h-indol-2-one

    35. Unii-71ia9s35aj

    36. (3z)-3-((3,5-dimethyl-1h-pyrrol-2-yl)methylidene)-1,3-dihydro-2h-indol-2-one

    37. (z)-semaxanib

    38. (z)-semaxinib

    39. Ncgc00094381-03

    40. 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one

    41. Nsc 696819

    42. 2x2m

    43. Semaxanib; Su5416

    44. Semaxanib [usan]

    45. Semaxanib [mart.]

    46. H-indol-2-one, 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)-1,3-dihydro-

    47. S 8442

    48. Schembl8190

    49. Semaxanib [who-dd]

    50. Lopac0_001110

    51. Schembl19571

    52. 1,3-dihydro-3-[(3,5-dimethyl-1h-pyrrol-2-yl)

    53. Mls001074896

    54. Mls001332519

    55. Mls001332520

    56. Bdbm4810

    57. Gtpl5056

    58. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one

    59. Chebi:91083

    60. Cid_5329098

    61. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one

    62. Bdbm497339

    63. Dtxsid801025708

    64. Hms2234l12

    65. Hms3229o13

    66. Hms3263m22

    67. Hms3268j13

    68. Hms3413h10

    69. Hms3648o12

    70. Hms3677h10

    71. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]indolin-2-one

    72. Amy10847

    73. Bcp06068

    74. Ex-a2158

    75. Tox21 111271

    76. Tox21_501110

    77. Hsci1_000303

    78. Mfcd09763655

    79. Nsc696819

    80. S2845

    81. Su5146

    82. Zinc12410091

    83. Akos015994557

    84. Ccg-205186

    85. Cs-1225

    86. Db06436

    87. Es-0010

    88. Lp01110

    89. Sdccgsbi-0051079.p003

    90. Us11001595, Compound Su5416

    91. Ncgc00094381-01

    92. Ncgc00094381-02

    93. Ncgc00094381-04

    94. Ncgc00094381-05

    95. Ncgc00094381-19

    96. Ncgc00261795-01

    97. Ac-35250

    98. Hy-10374

    99. Eu-0101110

    100. Sw219791-1

    101. D05819

    102. N11132

    103. A857052

    104. A899499

    105. 2h-indol-2-one,5-dimethyl-2-pyrrolyl)methylene]-

    106. J-013281

    107. Q7449140

    108. Sr-01000076044-2

    109. Sr-01000076044-8

    110. Brd-k63504947-001-05-5

    111. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinon

    112. 3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone

    113. 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)indolin-2-one

    114. Semaxanib, Semoxind, Tsu-16, Nsc-696819, Su-5416

    115. 3-[(3,5-dimethyl-2h-pyrrol-2-ylidene)methyl]-1h-indol-2-ol

    116. 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro- 2h-indol-2-one

    117. 3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one

    118. (3z)-3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one

    119. 2h-indol-2-one, 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)-1,3-dihydro-, (3z)-

    120. 2h-indol-2-one, 3-((3,5-dimethyl-1h-pyrrol-2-yl)methylene)-1,3-dihydro-, (z)-

    121. 2h-indol-2-one, 3-(3,5-dimethyl-1h-pyrrol-2-yl)methylene)- 1,3-dihydro-, (z)-

    122. 2h-indol-2-one, 3-(3,5-dimethyl-1h-pyrrol-2-yl)methylene)- 1,3-dihydro-,(z)-

    123. 2h-indol-2-one,3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-, (3z)-

    124. 3-[1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene]-2-oxo-2,3-dihydro-indole

    2.4 Create Date
    2005-03-26
    3 Chemical and Physical Properties
    Molecular Weight 238.28 g/mol
    Molecular Formula C15H14N2O
    XLogP32.5
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count1
    Rotatable Bond Count1
    Exact Mass238.110613074 g/mol
    Monoisotopic Mass238.110613074 g/mol
    Topological Polar Surface Area44.9 Ų
    Heavy Atom Count18
    Formal Charge0
    Complexity377
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in colorectal cancer and lung cancer.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Angiogenesis Inhibitors

    Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. (See all compounds classified as Angiogenesis Inhibitors.)

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)